Examinando por Materia "Drug combinations"

Mostrando 1 - 1 de 1
  • Publicación
    Acceso abierto
    Differences in health policies for drug availability in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension across Latin America
    (2022-01-05) Orozco‐Levi, Mauricio; Caneva, Jorge; Fernandes, Caio; Restrepo‐Jaramillo, Ricardo; Zayas, Nayeli; Conde, Rafael; Diez, Mirta; Jardim, Carlos; Pacheco-Gallego, Manuel C.; Melatini, Luciano; Valdez, Héctor; Pulido, Tomas; Masira
    Treatment for pulmonary arterial hypertension and chronic thromboembolicpulmonary hypertension in Latin America differs between countries, withregard to disease etiology, health insurance coverage, and drug availability. Agroup of experts from Latin America, met to share regional experiences andpropose possible lines of collaboration. The available evidence, regional clin-ical practice data, and the global context of the proceedings of the 6th WorldSymposium on Pulmonary Hypertension, held in Nice, France, in February2018, were analyzed. Here, we discuss some priority concepts identified that could guide transnational interaction and research strategies in Latin Amer-ica: (1) despite being evidence‐based, the 6th World Symposium on PulmonaryHypertension proceedings may not be applicable in Latin American countries;(2) proactive identification and diagnosis of patients in Latin America isneeded; (3) education of physicians and standardization of appropriate treat-ment for pulmonary arterial hypertension and chronic thromboembolic pul-monary hypertension is vital; (4) our clinical experience for the treatmentstrategy for pulmonary arterial hypertension and chronic thromboembolicpulmonary hypertension is based on drug availability in Argentina, Brazil,Colombia and México; (5) there are difficulties inherent to the consultation ofpatients with pulmonary arterial hypertension and chronic thromboembolicpulmonary hypertension, and access to treatment; (6) the importance of datageneration and research of Latin American‐specific issues related to pul-monary arterial hypertension and chronic thromboembolic pulmonary hy-pertension is highlighted.